NEW YORK (GenomeWeb) – Epigenetics sequencing firm Cambridge Epigenetix today announced the completion of a Series A financing round that raised $5.5 million.

The company also announced the appointment of Fedja Bobanovic as its CEO.

New Science Ventures led the financing, and founding investors Syncona Partners and Cambridge Enterprise participated in the round. Bobanovic said that the funds will be used to continue exploring commercial applications for the firm's products, as well as for R&D.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.